NEW YORK ( TheStreet) -- CHANGE IN RATINGS:Apple (AAPL - Get Report) was downgraded at Pacific Crest to sector perform. High end of the market appears saturated, Pacific Crest said. Estimates also cut.
STOCK COMMENTS / EPS CHANGESApple (AAPL - Get Report) estimates, target cut at BofA/Merrill. AAPL estimates were reduced through 2015, Bank of America/Merrill Lynch said. Company is facing increased smartphone competition. Buy rating and new $630 price target. Atmel (AMTL) estimates, target raised at Canaccord. Shares of ATML now seen reaching $8, according to Canaccord Genuity. Estimates also increased, given higher netbook touch penetration. Buy rating. Boeing (BA) cut from Conviction Buy List at Goldman. 787 risks continue to mount. $90 price target. Bristol Myers Squibb (BMY) numbers raised at Jefferies. Shares of BMY now seen reaching $39, Jefferies said. Estimates also raised on big year for clinical trial results. Buy rating. Eaton Vance (EV) numbers increased at BMO. EV estimates were raised through 2014, BMO Capital said. Company is attracting more assets. Market Perform rating and new $32 price target. Express (EXPR) estimates, target upped at BMO. EXPR estimates were boosted through 2013, BMO Capital said. Company saw higher demand throughout the holidays. Outperform rating and new $19 price target. Facebook (FB) target boosted at BofA/Merrill to $35. New advertising formats and mobile traction should continue to drive revenue acceleration. Buy rating. Google (GOOG) estimates lowered at Canaccord through 2014, Canaccord Genuity said. Expect lower Nexus margins and higher acquisition costs. Buy rating and $810 price target. Lululemon (LULU) estimates, target cut at Credit Suisse. Shares of LULU now seen reaching $79, according to Credit Suisse. Estimates also reduced, given moderating comp sales. Neutral rating. Marathon Oil (MRO) numbers raised at Oppenheimer. Shares of MRO now seen reaching $40, Oppenhiemer said. Estimates also raised on improved outlook. Outperform rating. Pfizer (PFE) numbers raised at Jefferies. Shares of PFE now seen reaching $31, Jefferies said. Estimates also raised on big year for clinical results. Buy rating. >To submit a news tip, email: email@example.com.
Twitter and become a fan on Facebook.